<?xml version="1.0" encoding="UTF-8"?>
<p>Secondly, studies on the design of antiviral agents based on the structure and function of viral and human receptor proteins (Sub-Cluster 2-2) included 31 projects totaling 76,626,049 USD. In the US, The University of North Carolina Chapel Hill and Kansas State University committed to spending 6.5 million USD on a project named “Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV” between 2017 and 2022, and to 3.8 million USD worth of a project entitled “Small molecule protease inhibitors against MERS-CoV” between 2018 and 2023. In Japan, the Nippon Veterinary and Life Science University finished “The development of specific anticoronavirus drugs using the novel glycosidase inhibitors”, spending 144,000 USD between 2016 and 2019 (see 
 <xref rid="healthcare-08-00204-t006" ref-type="table">Table 6</xref>).
</p>
